Stock PRLD PRELUDE THERAPEUTICS INCORPORATED
Add to a list
To use this feature you must be a member
Log inSign up

Financials Prelude Therapeutics Incorporated

Equities

PRLD

US74065P1012

Biotechnology & Medical Research

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-04-26 pm EDT 		5-day change 1st Jan Change
4.07 USD +0.74% Intraday chart for Prelude Therapeutics Incorporated +9.41% -4.68%
Apr. 10 Bryant D. Lim to Serve as Principal Financial Officer and Principal Accounting Officer of Prelude Therapeutics Incorporated CI
Apr. 10 Prelude Therapeutics Incorporated Announces Chief Financial Officer Changes CI

Valuation

Fiscal Period: December 2020 2021 2022 2023 2024 2025 2026
Capitalization 1 3,033 577.3 287.4 267.8 223.4 - -
Enterprise Value (EV) 1 2,815 286.1 85.7 34.85 16.02 62.44 223.4
P/E ratio -15.7 x -5.12 x -2.48 x -2.11 x -2.01 x -2.15 x -2.5 x
Yield - - - - - - -
Capitalization / Revenue - - - - - - -
EV / Revenue - - - - - - -
EV / EBITDA -48.3 x -2.54 x -0.7 x -0.27 x -0.1 x -0.35 x -
EV / FCF - - -987,949 x - - - -
FCF Yield - - -0% - - - -
Price to Book 11 x 1.58 x 1.46 x 0.99 x 1.71 x 2.95 x -
Nbr of stocks (in thousands) 42,391 46,373 47,588 62,714 54,894 - -
Reference price 2 71.55 12.45 6.040 4.270 4.070 4.070 4.070
Announcement Date 3/16/21 3/16/22 3/15/23 2/15/24 - - -
1USD in Million2USD
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2020 2021 2022 2023 2024 2025 2026
Net sales 1 - - - - - - -
EBITDA 1 -58.22 -112.8 -122.2 -131.1 -157.6 -177.7 -
EBIT 1 -58.76 -113.7 -123.5 -132.3 -153.9 -175.3 -180.1
Operating Margin - - - - - - -
Earnings before Tax (EBT) 1 - - -115.4 - -139.9 -159 -178.5
Net income 1 -56.93 -111.7 -115.4 -121.8 -139.7 -159 -178.5
Net margin - - - - - - -
EPS 2 -4.560 -2.430 -2.440 -2.020 -2.025 -1.890 -1.630
Free Cash Flow - - -86.75 - - - -
FCF margin - - - - - - -
FCF Conversion (EBITDA) - - - - - - -
FCF Conversion (Net income) - - - - - - -
Dividend per Share - - - - - - -
Announcement Date 3/16/21 3/16/22 3/15/23 2/15/24 - - -
1USD in Million2USD
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: December 2021 Q3 2021 Q4 2022 Q1 2022 Q2 2022 Q3 2022 Q4 2023 Q1 2023 Q2 2023 Q3 2023 Q4 2024 Q1 2024 Q2 2024 Q3 2024 Q4 2025 Q1
Net sales 1 - - - - - - - - - - - - - - -
EBITDA - - -29.98 -29.14 -30.07 - - - - - - - - - -
EBIT 1 -30.84 -33.01 -30.29 -29.46 -30.41 -33.38 -29.12 -32.4 -33.38 -37.38 -36.64 -37.25 -37.87 -39.52 -
Operating Margin - - - - - - - - - - - - - - -
Earnings before Tax (EBT) 1 - - - -27.37 -29.96 -28.64 -27.72 -30.43 -30.61 - -33.38 -34.1 -34.83 -37.58 -
Net income 1 -30.69 -32.84 -29.46 -27.37 -29.96 -28.64 -27.72 -30.43 -30.61 -33.08 -33.29 -34.2 -35.13 -37.08 -
Net margin - - - - - - - - - - - - - - -
EPS 2 -0.6600 -0.7100 -0.6300 -0.5800 -0.6300 -0.6000 -0.5800 -0.5400 -0.4500 -0.4500 -0.4950 -0.5050 -0.5200 -0.5050 -0.4600
Dividend per Share - - - - - - - - - - - - - - -
Announcement Date 11/12/21 3/16/22 5/10/22 8/9/22 11/14/22 3/15/23 5/8/23 8/3/23 11/1/23 2/15/24 - - - - -
1USD in Million2USD
Estimates

Balance Sheet Analysis

Fiscal Period: December 2020 2021 2022 2023 2024 2025 2026
Net Debt 1 - - - - - - -
Net Cash position 1 218 291 202 233 207 161 -
Leverage (Debt/EBITDA) - - - - - - -
Free Cash Flow - - -86.7 - - - -
ROE (net income / shareholders' equity) -69.9% -44.8% -48% -56.3% -71.5% -107% -
ROA (Net income/ Total Assets) - - - - - - -
Assets 1 - - - - - - -
Book Value Per Share 2 6.510 7.900 4.130 4.320 2.380 1.380 -
Cash Flow per Share -3.700 -1.810 -1.770 - - - -
Capex - - - - - - -
Capex / Sales - - - - - - -
Announcement Date 3/16/21 3/16/22 3/15/23 2/15/24 - - -
1USD in Million2USD
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
5
Last Close Price
4.07 USD
Average target price
4.75 USD
Spread / Average Target
+16.71%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

1st Jan change Capi.
PRELUDE THERAPEUTICS INCORPORATED Stock Prelude Therapeutics Incorporated
-4.68% 223M
IQVIA HOLDINGS INC. Stock Iqvia Holdings Inc.
+1.51% 42.75B
MODERNA, INC. Stock Moderna, Inc.
+8.57% 41.34B
LONZA GROUP AG Stock Lonza Group AG
+49.22% 41.61B
CELLTRION, INC. Stock Celltrion, Inc.
-12.36% 26.59B
ICON PUBLIC LIMITED COMPANY Stock ICON Public Limited Company
+8.92% 25.49B
ALNYLAM PHARMACEUTICALS, INC. Stock Alnylam Pharmaceuticals, Inc.
-25.13% 18.12B
MEDPACE HOLDINGS, INC. Stock Medpace Holdings, Inc.
+29.17% 12.24B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. Stock Charles River Laboratories International, Inc.
-3.12% 11.76B
UNITED THERAPEUTICS CORPORATION Stock United Therapeutics Corporation
+6.35% 11B
Other Biotechnology & Medical Research
  1. Stock Market
  2. Equities
  3. PRLD Stock
  4. Financials Prelude Therapeutics Incorporated